Bill Maughan
Stock Analyst at Canaccord Genuity
(0.16)
# 3,714
Out of 4,667 analysts
14
Total ratings
16.67%
Success rate
-22.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $26 | $10.10 | +157.43% | 2 | Aug 13, 2024 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $2.44 | +514.75% | 2 | May 10, 2024 | |
| FATE Fate Therapeutics | Maintains: Buy | $11 → $9 | $2.07 | +334.78% | 1 | May 10, 2024 | |
| IMCR Immunocore Holdings | Maintains: Hold | $63 → $67 | $32.12 | +108.59% | 3 | May 9, 2024 | |
| MRNA Moderna | Maintains: Hold | $91 → $106 | $38.25 | +177.12% | 3 | May 3, 2024 | |
| IPSC Century Therapeutics | Maintains: Buy | $22 → $24 | $1.24 | +1,835.48% | 1 | Mar 15, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $60 | $20.26 | +196.15% | 1 | Feb 21, 2024 | |
| MRUS Merus | Initiates: Buy | $45 | $44.36 | +1.45% | 1 | Nov 2, 2023 |
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Buy
Price Target: $26
Current: $10.10
Upside: +157.43%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.44
Upside: +514.75%
Fate Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $2.07
Upside: +334.78%
Immunocore Holdings
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $32.12
Upside: +108.59%
Moderna
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $38.25
Upside: +177.12%
Century Therapeutics
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $1.24
Upside: +1,835.48%
Bicycle Therapeutics
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $20.26
Upside: +196.15%
Merus
Nov 2, 2023
Initiates: Buy
Price Target: $45
Current: $44.36
Upside: +1.45%